THE TAPE
RGEN · Biotechnology · $9.2B

Repligen Corp

$162.78▼ −2.99%
Last close
Relative strength
76RS
of 99, against every stock▼ -5 on the month
Cooling off
Unconfirmed
+27.2%
six months against Biotechnology
52-week range
−18.1%
from the high
$100.99$198.87
Setup
squeezeforming
−14.8%
against the pivot at $191.05
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue +11% on a year ago
11/16 O 166.14 H 166.79 L 162.48 Vol 575.4K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS76
vs pivot−14.80%
Tightening1.17×
Dry-up2.03×
Up/down vol-0.09
From high18%
forming3 of 9checks
Cooling off
Support and resistance
Support below
$148.23
-8.9% · tested 4× · last 81 sessions ago
Resistance above
$170.21
+4.6% · tested 5× · last 7 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 2.8 weeks and fell 14% from its ceiling at its deepest. The pivot is $191.05, and the stock closed 14.8% below it. Its relative strength rating is 76.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-9.8%
Three months against its industry
+4.5%
Six months against its industry
+27.2%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 4.9% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$805.6M
+10.9% year on year
Operating margin
2.3%
Net margin
-1.5%
Free cash flow
$106.7M
1.2% of market cap
Price to sales
11.4×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 27
Key takeaway
A mixed quarter: the numbers do not agree.
Revenue
$209.3M
+2.5% QoQ · +10.9% YoY
Gross margin
—
Net income
−$38.4M
Loss
Free cash flow
$38.2M
Cash generating

What the numbers say

  • Revenue +10.9% year over year, +2.5% on the quarter
  • Weak: Net loss $38M
  • Good: Cash generating: operating cash flow $43M, free cash flow $38M
  • Good: Net cash $171M · cash $727M
Revenue by quarter
Free cash flow
Net income
shares 0.0% in a year · net cash $171.4M

What is not obvious

  • Weak: Interest $6M a quarter against an operating loss: the debt is carried by the balance sheet, not operations
Final read
Growth: FLAT · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is operating profit: net loss $38M.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 5 of 46 tracked funds at the end of Q3 2026.

Last quarter: 2 bought new, 2 added, 1 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Entered a material agreementFiling · 2026-11-07
1.01
No measurable effect: stocks behave like random ones over the next three sessions (866 cases over 54 nights).
GappedTape · 2026-11-06
-5.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-10-31
below 20d & 50d on 3.4x volume at 176.94
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-10-31
-6.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-10-31
7.5 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
GappedTape · 2026-10-29
+5.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Red flag in a filingFiling · 2026-10-28
restatement
No measurable effect: stocks behave like random ones over the next three sessions (1,160 cases over 54 nights).
Closed below its 20- and 50-day on heavy volumeTape · 2026-10-28
below 20d & 50d on 1.7x volume at 175.80
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news

No headlines for this company in the last couple of weeks.

Insiders
Bought on the open market
0
Sold on the open market
9
$6,139,045 total

Sold: Loeillot Olivier, Garland Jason K.

Not counted above: 10 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-06 Douglass Brian Robb · CHIEF PRODUCT OFFICERaward700
2026-10-05 Loeillot Olivier · Chief Executive Officer, Directorsell1,333$238,274
2026-10-05 Loeillot Olivier · Chief Executive Officer, Directoroption exercise4,202$651,142
2026-10-05 Loeillot Olivier · Chief Executive Officer, Directorsell4,202$798,380
2026-10-02 Loeillot Olivier · Chief Executive Officer, Directorwithheld for tax1,248$226,762
2026-09-25 Garland Jason K · CFOwithheld for tax421$79,855
2026-09-24 Loeillot Olivier · Chief Executive Officer, Directoroption exercise8,404$1,302,284
2026-09-24 Loeillot Olivier · Chief Executive Officer, Directorsell8,404$1,596,760

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
Level · ceiling$191.05
Wrong below$161.70
Measured target · a squeeze has no height to projectnone
Through to the apex64%
Leaning · and easingdown
Length2.8 weeks

Leaning is where price has been sitting against its own range while the range was quiet. It is not a forecast of which way the range opens up, and this site has no measurement that would support one.

What lines up

3 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy3
Buy13
Hold4
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Repligen Corp (RGEN) — The Tape